• A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients 

      Jenum, Synne; Tonby, Kristian; Rueegg, Corina Silvia; Ruhwald, Morten; Kristiansen, Max Per; Bang, Peter; Olsen, Inge Christoffer; Sellæg, Kjersti; Røstad, Kjerstin; Mustafa, Tehmina; Tasken, Kjetil; Kvale, Dag; Mortensen, Rasmus; Riise, Anne Margarita Dyrhol (Journal article; Peer reviewed, 2021)
      Host-directed-therapy strategies are warranted to fight tuberculosis. Here we assess the safety and immunogenicity of adjunctive vaccination with the H56:IC31 candidate and cyclooxygenase-2-inhibitor treatment (etoricoxib) ...